Serum tumor markers alone can provide reliable surveillance of patients who undergo total thyroidectomy for low- and intermediate-risk papillary thyroid carcinoma.
Rozlytrek is a kinase inhibitor that selectively targets ROS1 and NTRK fusions.
Many patients diagnosed with differentiated thyroid cancer perceive that they have no choice about receiving radioactive iodine.
When the investigators included extranodal extension in the ATA’s current PTC risk stratification system, 32.8% of patients originally categorized as low risk with ≤5 positive lymph nodes were increased to intermediate risk.
Incidence rates of pediatric thyroid cancer have increased in the United States, likely attributable to enhanced diagnostic practices and an increase in thyroid cancer in the pediatric population.
Standardized incidence ratio highest for prostate cancer for men, nasopharynx cancer for women
Treatment with once-weekly exenatide 2 mg does not increase serum calcitonin concentrations or the risk for medullary thyroid carcinoma.
Patients who initially received negative thyroid biopsy results might face higher cumulative risk of developing thyroid cancer than that projected in previous literature.
Complication rates are low following surgery for pediatric thyroid disease at a high-volume center.
A multigene genomic classifier (GC) test for thyroid nodules with indeterminate cytology shows high sensitivity and negative predictive value.
The best overall performance was that of the ACR Thyroid Imaging Reporting and Data System, which classified more than half of the requested biopsies as unnecessary.